BACKGROUND: Vaccine-induced immunity against pneumococcal infection relies on the generation of high concentrations of antibody and B cell memory. Both the 10- and the 13-valent pneumococcal conjugate vaccines (PCV-10 and PCV-13) effectively reduce disease caused by vaccine serotypes. It is unknown whether the generation of B cell memory requires several doses of the same vaccine or whether different PCVs are interchangeable. METHODS:Children in the United Kingdom (n=178) who had previously received PCV-13 at 2 and 4 months were randomized 1:1 to receive a PCV-13 or PCV-10 booster at age 12 months. Peripheral blood memory B cells (BMEM) were quantified before and at 1 and 12 months after vaccination using a cultured enzyme-linked immunospot assay for pneumococcal serotypes 1, 3, 4, 9V, 14, 19A, and diphtheria and tetanus toxoid. Correlations between BMEM frequencies and simultaneously measured antibody (IgG and opsonophagocytic assay) was also assessed. RESULTS: A significant rise in postbooster BMEM frequency was seen for 5 out of 6 serotypes in the PCV-13 group and none in the PCV-10 group. In the PCV-13 group, there was a particularly large increase in serotype 3-specific BMEM associated with only a small increase in antibody. Postbooster BMEM responses correlated positively with antibody, but correlations between prebooster BMEM and subsequent BMEM and antibody responses were inconsistent. CONCLUSIONS: After priming with PCV-13 in early infancy, a booster dose of PCV-10 does not induce detectable peripheral blood BMEM responses but a PCV-13 booster does induce robust responses. Booster responses to PCVs may be dependent on homologous carrier protein priming.
RCT Entities:
BACKGROUND: Vaccine-induced immunity against pneumococcal infection relies on the generation of high concentrations of antibody and B cell memory. Both the 10- and the 13-valent pneumococcal conjugate vaccines (PCV-10 and PCV-13) effectively reduce disease caused by vaccine serotypes. It is unknown whether the generation of B cell memory requires several doses of the same vaccine or whether different PCVs are interchangeable. METHODS:Children in the United Kingdom (n=178) who had previously received PCV-13 at 2 and 4 months were randomized 1:1 to receive a PCV-13 or PCV-10 booster at age 12 months. Peripheral blood memory B cells (BMEM) were quantified before and at 1 and 12 months after vaccination using a cultured enzyme-linked immunospot assay for pneumococcal serotypes 1, 3, 4, 9V, 14, 19A, and diphtheria and tetanus toxoid. Correlations between BMEM frequencies and simultaneously measured antibody (IgG and opsonophagocytic assay) was also assessed. RESULTS: A significant rise in postbooster BMEM frequency was seen for 5 out of 6 serotypes in the PCV-13 group and none in the PCV-10 group. In the PCV-13 group, there was a particularly large increase in serotype 3-specific BMEM associated with only a small increase in antibody. Postbooster BMEM responses correlated positively with antibody, but correlations between prebooster BMEM and subsequent BMEM and antibody responses were inconsistent. CONCLUSIONS: After priming with PCV-13 in early infancy, a booster dose of PCV-10 does not induce detectable peripheral blood BMEM responses but a PCV-13 booster does induce robust responses. Booster responses to PCVs may be dependent on homologous carrier protein priming.
Authors: Marta Valente Pinto; Daniel O'Connor; Ushma Galal; Elizabeth A Clutterbuck; Hannah Robinson; Emma Plested; Sagida Bibi; Susana Camara Pellisso; Harri Hughes; Simon Kerridge; Yama F Mujadidi; Helen Findlow; Ray Borrow; Matthew D Snape; Andrew J Pollard Journal: Open Forum Infect Dis Date: 2020-04-29 Impact factor: 3.835
Authors: Sara Pischedda; Daniel O'Connor; Benjamin P Fairfax; Antonio Salas; Federico Martinon-Torres; Andrew J Pollard; Johannes Trück Journal: Clin Epigenetics Date: 2021-02-04 Impact factor: 6.551
Authors: Suhi Jeon; Meagan Kelly; Jeesun Yun; Byungman Lee; Minchul Park; Yoonhee Whang; Chankyu Lee; Yuan-Di Halvorsen; Smriti Verma; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Daniel T Leung; Taufiqur R Bhuiyan; Firdausi Qadri; Mohammad Kamruzzaman; Somyoung Cho; Willie F Vann; Peng Xu; Pavol Kováč; Ravi Ganapathy; Julia Lynch; Edward T Ryan Journal: Vaccine Date: 2021-10-27 Impact factor: 3.641